BACKGROUND: The current World Health Organization classification of myelodysplastic syndromes is based morphological evaluation of bone marrow dysplasia. In clinical practice, the reproducibility of the recognition of dysplasia is usually poor especially in cases that lack specific markers such as ring sideroblasts and clonal cytogenetic abnormalities. DESIGN AND METHODS: We aimed to develop and validate a flow cytometric score for the diagnosis of myelodysplastic syndrome. Four reproducible parameters were analyzed: CD34(+) myeloblast-related and B-progenitor-related cluster size (defined by CD45 expression and side scatter characteristics CD34(+) marrow cells), myeloblast CD45 expression and granulocyte side scatter value. The study comprised a "learning cohort" (n=538) to define the score and a "validation cohort" (n=259) to confirm its diagnostic value. RESULTS: With respect to non-clonal cytopenias, patients with myelodysplastic syndrome had increased myeloblast-related cluster size, decreased B-progenitor-related cluster size, aberrant CD45 expression and reduced granulocyte side scatter (P<0.001). To define the flow cytometric score, these four parameters were combined in a regression model and the weight for each variable was estimated based on coefficients from that model. In the learning cohort a correct diagnosis of myelodysplastic syndrome was formulated in 198/281 cases (sensitivity 70%), while 18 false-positive results were noted among 257 controls (specificity 93%). Sixty-five percent of patients without specific markers of dysplasia (ring sideroblasts and clonal cytogenetic abnormalities) were correctly classified. A high value of the flow cytometric score was associated with multilineage dysplasia (P=0.001), transfusion dependency (P=0.02), and poor-risk cytogenetics (P=0.04). The sensitivity and specificity in the validation cohort (69% and 92%, respectively) were comparable to those in the learning cohort. The likelihood ratio of the flow cytometric score was 10. CONCLUSIONS: A flow cytometric score may help to establish the diagnosis of myelodysplastic syndrome, especially when morphology and cytogenetics are indeterminate.
BACKGROUND: The current World Health Organization classification of myelodysplastic syndromes is based morphological evaluation of bone marrow dysplasia. In clinical practice, the reproducibility of the recognition of dysplasia is usually poor especially in cases that lack specific markers such as ring sideroblasts and clonal cytogenetic abnormalities. DESIGN AND METHODS: We aimed to develop and validate a flow cytometric score for the diagnosis of myelodysplastic syndrome. Four reproducible parameters were analyzed: CD34(+) myeloblast-related and B-progenitor-related cluster size (defined by CD45 expression and side scatter characteristics CD34(+) marrow cells), myeloblast CD45 expression and granulocyte side scatter value. The study comprised a "learning cohort" (n=538) to define the score and a "validation cohort" (n=259) to confirm its diagnostic value. RESULTS: With respect to non-clonal cytopenias, patients with myelodysplastic syndrome had increased myeloblast-related cluster size, decreased B-progenitor-related cluster size, aberrant CD45 expression and reduced granulocyte side scatter (P<0.001). To define the flow cytometric score, these four parameters were combined in a regression model and the weight for each variable was estimated based on coefficients from that model. In the learning cohort a correct diagnosis of myelodysplastic syndrome was formulated in 198/281 cases (sensitivity 70%), while 18 false-positive results were noted among 257 controls (specificity 93%). Sixty-five percent of patients without specific markers of dysplasia (ring sideroblasts and clonal cytogenetic abnormalities) were correctly classified. A high value of the flow cytometric score was associated with multilineage dysplasia (P=0.001), transfusion dependency (P=0.02), and poor-risk cytogenetics (P=0.04). The sensitivity and specificity in the validation cohort (69% and 92%, respectively) were comparable to those in the learning cohort. The likelihood ratio of the flow cytometric score was 10. CONCLUSIONS: A flow cytometric score may help to establish the diagnosis of myelodysplastic syndrome, especially when morphology and cytogenetics are indeterminate.
Authors: L Malcovati; M G Della Porta; M Lunghi; C Pascutto; L Vanelli; E Travaglino; M Maffioli; P Bernasconi; M Lazzarino; R Invernizzi; M Cazzola Journal: Leukemia Date: 2005-05 Impact factor: 11.528
Authors: F Ramos; S Fernández-Ferrero; D Suárez; M Barbón; J A Rodríguez; S Gil; M Megido; J Ciudad; N López; C del Cañizo; A Orfao Journal: Leuk Res Date: 1999-03 Impact factor: 3.156
Authors: Holden T Maecker; J Philip McCoy; Michael Amos; John Elliott; Adolfas Gaigalas; Lili Wang; Richard Aranda; Jacques Banchereau; Chris Boshoff; Jonathan Braun; Yael Korin; Elaine Reed; Judy Cho; David Hafler; Mark Davis; C Garrison Fathman; William Robinson; Thomas Denny; Kent Weinhold; Bela Desai; Betty Diamond; Peter Gregersen; Paola Di Meglio; Paola DiMeglio; Frank O Nestle; Frank Nestle; Mark Peakman; Federica Villanova; Federica Villnova; John Ferbas; Elizabeth Field; Aaron Kantor; Thomas Kawabata; Wendy Komocsar; Michael Lotze; Jerry Nepom; Hans Ochs; Raegan O'Lone; Deborah Phippard; Scott Plevy; Stephen Rich; Mario Roederer; Dan Rotrosen; Jung-Hua Yeh Journal: Nat Immunol Date: 2010-11 Impact factor: 25.606
Authors: Denise A Wells; Martin Benesch; Michael R Loken; Carlos Vallejo; David Myerson; Wendy M Leisenring; H Joachim Deeg Journal: Blood Date: 2003-03-20 Impact factor: 22.113
Authors: Alexander Sternberg; Sally Killick; Tim Littlewood; Chris Hatton; Andy Peniket; Thomas Seidl; Shamit Soneji; Joanne Leach; David Bowen; Claire Chapman; Graham Standen; Edwin Massey; Lisa Robinson; Bipin Vadher; Richard Kaczmarski; Riaz Janmohammed; Kim Clipsham; Andrew Carr; Paresh Vyas Journal: Blood Date: 2005-08-02 Impact factor: 22.113
Authors: Josephine D Kahn; Martine E D Chamuleau; Theresa M Westers; Peter M Van de Ven; Linda van Dreunen; Margot van Spronsen; Gert J Ossenkoppele; Arjan A van de Loosdrecht Journal: Haematologica Date: 2015-03-06 Impact factor: 9.941
Authors: Michaela Nováková; Markéta Žaliová; Martina Suková; Marcin Wlodarski; Aleš Janda; Eva Froňková; Vít Campr; Kateřina Lejhancová; Ondřej Zapletal; Dagmar Pospíšilová; Zdeňka Černá; Tomáš Kuhn; Peter Švec; Vendula Pelková; Zuzana Zemanová; Gitte Kerndrup; Marry van den Heuvel-Eibrink; Vincent van der Velden; Charlotte Niemeyer; Tomáš Kalina; Jan Trka; Jan Starý; Ondřej Hrušák; Ester Mejstříková Journal: Haematologica Date: 2016-03-24 Impact factor: 9.941
Authors: Eline M P Cremers; Theresia M Westers; Canan Alhan; Claudia Cali; Heleen A Visser-Wisselaar; Dana A Chitu; Vincent H J van der Velden; Jeroen G Te Marvelde; Saskia K Klein; Petra Muus; Edo Vellenga; Georgina E de Greef; Marie-Cecile C J C Legdeur; Pierre W Wijermans; Marian J P L Stevens-Kroef; Pedro da Silva-Coelho; Joop H Jansen; Gert J Ossenkoppele; Arjan A van de Loosdrecht Journal: Haematologica Date: 2016-09-22 Impact factor: 9.941